Stockscreener 앱 받기
39.95
0.53%
0.21
시간 외 거래:
39.17
-0.78
-1.95%
전일 마감가:
$39.74
열려 있는:
$39.86
하루 거래량:
812.86K
Relative Volume:
0.47
시가총액:
$8.20B
수익:
-
순이익/손실:
$-505.61M
주가수익비율:
-14.42
EPS:
-2.7697
순현금흐름:
$-407.32M
1주 성능:
+3.44%
1개월 성능:
-0.35%
6개월 성능:
+47.69%
1년 성능:
+153.97%
1일 변동 폭
$38.95
$40.33
1주일 범위
$36.78
$40.33
52주 변동 폭
$14.32
$41.23
Immunovant Inc Stock (IMVT) Company Profile
명칭
Immunovant Inc
전화
917-410-3120
주소
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
39.95 | 8.23B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Mkt Perform |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 개시 | Truist | Hold |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-03-03 | 개시 | Jefferies | Hold |
| 2025-01-03 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-09 | 재확인 | Oppenheimer | Outperform |
| 2024-03-28 | 개시 | Oppenheimer | Outperform |
| 2024-03-13 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | JP Morgan | Overweight |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-13 | 업그레이드 | UBS | Neutral → Buy |
| 2023-09-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 개시 | BofA Securities | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-31 | 개시 | Piper Sandler | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2023-02-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2021-08-03 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-01 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-12 | 개시 | Guggenheim | Buy |
| 2020-10-08 | 개시 | Stifel | Buy |
| 2020-10-02 | 개시 | Credit Suisse | Outperform |
| 2020-08-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-07-29 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | SVB Leerink | Outperform |
모두보기
Immunovant Inc 주식(IMVT)의 최신 뉴스
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy - Seeking Alpha
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Immunovant Inc (IMVT) Cash Flow - TradingKey
Immunovant Insider Sold Shares Worth $263,015, According to a Recent SEC Filing - marketscreener.com
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IMVT|Immunovant Inc|Price:39.410|Chg%:+0.040 - TradingKey
Immunovant CFO Tiago Girao sells $263,014 in company stock By Investing.com - Investing.com India
Immunovant director Atul Pande sells $59,699 in shares By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells $59,699 in shares - Investing.com
Immunovant CFO Tiago Girao sells $263,014 in company stock - Investing.com
Immunovant CTO Jay Stout sells $110,537 in shares - Investing.com
Form 4 Immunovant Inc For: 24 July By Investing.com - Investing.com Nigeria
Immunovant CTO Jay Stout Executes Share Sale to Meet Tax Obligations Post-RSU Vesting - Kalkine Media
Immunovant (IMVT) CTO sells 2,857 shares in mandated tax sell-to-cover - Stock Titan
Immunovant director Atul Pande disposes of 1,500 common shares for $59,700 - Bitget
Immunovant updates financial calendar with first-quarter results release and business update call - Bitget
Immunovant, Inc. ($IMVT) CEO 2026 Pay Revealed - Quiver Quantitative
Immunovant, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
Immunovant (NASDAQ: IMVT) plans 2026 votes on directors, auditor and pay - Stock Titan
Law firm investigates Immunovant officers for p... - Pluang
Understanding Momentum Shifts in (IMVT) - Stock Traders Daily
Immunovant Inc. (IMVT) Q2 2026 Earnings: Wider-than-Expected Loss Highlights Ongoing R&D InvestmentOne-Time Loss Impact - dars.gov.et
Immunovant chief legal officer Van Tuyl sells $47,702 in stock By Investing.com - Investing.com India
Immunovant CTO Jay Stout sells $137,924 in IMVT stock - Investing.com
Immunovant CTO Jay Stout sells $137,924 in IMVT stock By Investing.com - Investing.com South Africa
Form 4 Immunovant Inc For: 10 July By Investing.com - Investing.com Nigeria
Immunovant chief legal officer Van Tuyl sells $47,702 in stock - Investing.com
Immunovant COO Melanie Gloria sells $80,531 in shares By Investing.com - Investing.com South Africa
Immunovant COO Melanie Gloria sells $80,531 in shares - Investing.com
Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding - Stock Titan
Immunovant (IMVT) legal chief sells 1,206 shares in tax “sell to cover” - Stock Titan
Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales - Stock Titan
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53 - Moomoo
Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
Immunovant Inc explores long term growth paths as autoimmune pipeline advances - Ad-hoc-news.de
Immunovant stock hits 52-week high at 39.28 USD By Investing.com - Investing.com South Africa
Immunovant stock hits 52-week high at 39.28 USD - Investing.com
Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones - Ad-hoc-news.de
Form 4 Immunovant Inc For: 6 July By Investing.com - Investing.com Nigeria
Immunovant CEO Eric Venker sells $118,980 of IMVT stock - Investing.com UK
Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com - Investing.com Nigeria
Immunovant Inc (IMVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunovant Inc 주식 (IMVT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
Jul 24 '26 |
Sale |
39.80 |
1,500 |
59,700 |
116,731 |
| Girao Tiago | Chief Financial Officer |
Jul 23 '26 |
Sale |
38.69 |
6,798 |
263,015 |
240,798 |
| Stout Jay S | Chief Technology Officer |
Jul 23 '26 |
Sale |
38.69 |
2,857 |
110,537 |
205,341 |
| Gloria Melanie | Chief Operating Officer |
Jul 08 '26 |
Sale |
39.55 |
2,036 |
80,532 |
222,357 |
| Van Tuyl Christopher | Chief Legal Officer |
Jul 08 '26 |
Sale |
39.55 |
1,206 |
47,702 |
179,391 |
| Stout Jay S | Chief Technology Officer |
Jul 08 '26 |
Sale |
39.55 |
3,487 |
137,925 |
208,198 |
| Venker Eric | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
14.46 |
92,188 |
1,333,038 |
344,001 |
| Venker Eric | Chief Executive Officer |
Jul 02 '26 |
Sale |
38.48 |
3,092 |
118,980 |
254,280 |
| Gloria Melanie | Chief Operating Officer |
Jun 26 '26 |
Sale |
38.31 |
17,714 |
678,604 |
224,393 |
| Stout Jay S | Chief Technology Officer |
Jun 26 '26 |
Sale |
38.31 |
40,000 |
1,532,309 |
211,685 |
1.84%
0.86%
자본화:
|
볼륨(24시간):